Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy.

ABSTRACT:

Background

Less than half of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) patients respond to trastuzumab plus chemotherapy, and the outcomes are unsatisfactory. Understanding the underlying mechanisms remains crucial for identifying patients who are more likely to benefit from treatment.

Patients and methods

We performed targeted DNA sequencing on paired pre-treatment and progressive tumour tissues from 22 HER2-positive advanced GC patients undergoing first-line treatment with trastuzumab and chemotherapy. Clinicopathological and genomic characteristics were assessed for the correlation with clinical outcomes.

Results

A performance status (PS) of 0-1 was associated with improved progression-free survival (PFS) and overall survival

SUBMITTER: Lei Y 

PROVIDER: S-EPMC12599165 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature